Double-blind, Randomized, Placebo-Controlled Phase III Study Evaluating Efficacy and Safety of Subcutaneous Human Immunoglobulin (Octanorm) in Patients With Dermatomyositis (SCGAM-02)
Phase of Trial: Phase III
Latest Information Update: 26 Feb 2019
Price : $35 *
At a glance
- Drugs Immune globulin (Primary)
- Indications Dermatomyositis
- Focus Registrational; Therapeutic Use
- Sponsors Octapharma
- 20 Feb 2019 Status changed from recruiting to discontinued due to study complexity, low study recruitment
- 13 Dec 2018 This trial has been completed in Czech Republic , according to European Clinical Trials Database.
- 31 Oct 2018 Planned End Date changed from 1 Mar 2020 to 1 Jun 2020.